Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL20377426

N.N.O=C(O)CCC(=O)CC(=O)O

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHF8 Q9UPP1 6/20 0.62
KDM2A Q9Y2K7 6/20 0.62
EGLN1 Q9GZT9 5/20 0.62
KDM4E B2RXH2 4/20 0.62
KDM5C P41229 4/20 0.62
KDM6B O15054 2/20 0.62
LMNA P02545 4/20 0.56
ALKBH5 Q6P6C2 1/20 0.56
SUCNR1 Q9BXA5 1/20 0.56
GABRR1 P24046 1/20 0.52
ACE P12821 1/20 0.50
LDHA P00338 1/20 0.47
SRR Q9GZT4 1/20 0.47
FOLH1 Q04609 1/20 0.46
SLC15A2 Q16348 1/20 0.43
MAPK1 P28482 1/20 0.43
SLC13A3 Q8WWT9 1/20 0.43
OR51E2 Q9H255 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.42
TSHR P16473 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL218098 0.97 PHF8 (0.65) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL30572348 0.97 PHF8 (0.65) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377444 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377423 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377434 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL6914036 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377443 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377429 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
SCHEMBL20377438 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C
Hydrogen Sulfide SCHEMBL28240428 0.94 PHF8 (0.62) PHF8KDM2AEGLN1KDM4EKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364218-B2 Method of producing epsilon-caprolactam TORAY INDUSTRIES, INC. (JP) 2019-07-30 US disclosed
US-20180237389-A1 METHOD OF PRODUCING EPSILON-CAPROLACTAM TORAY INDUSTRIES, INC. (JP) 2018-08-23 US disclosed
EP-3348544-A1 METHOD FOR PRODUCING -CAPROLACTAM Toray Industries, Inc. (JP) 2018-07-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364218-B2 Method of producing epsilon-caprolactam CAPRIN1, PTMA, CYP51A1 PHF8 3382/4885KDM2A 4540/4885EGLN1 476/4885
US-20180237389-A1 METHOD OF PRODUCING EPSILON-CAPROLACTAM CAPRIN1, PTMA, CYP51A1 PHF8 3382/4885KDM2A 4540/4885EGLN1 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.